These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 8689858

  • 1. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance.
    Chiasson JL.
    Diabet Med; 1996; 13(3 Suppl 2):S23-4. PubMed ID: 8689858
    [Abstract] [Full Text] [Related]

  • 2. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance.
    Chiasson JL, Josse RG, Leiter LA, Mihic M, Nathan DM, Palmason C, Cohen RM, Wolever TM.
    Diabetes Care; 1996 Nov; 19(11):1190-3. PubMed ID: 8908378
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
    Yamagishi S, Nakamura K, Takeuchi M.
    Med Hypotheses; 2005 Nov; 65(1):152-4. PubMed ID: 15893133
    [Abstract] [Full Text] [Related]

  • 4. Effects of acarbose in patients with beta-thalassaemia major and abnormal glucose homeostasis.
    Mangiagli A, Campisi S, De Sanctis V, Nicoletti MC, Cardinale G, Galati MC, Raiola G, Rigano P, Saviano A, Study Group of the Italian Pediatric and Diabetes Soceity (SIEDP) on Endocrine Complicaionts in Non-Endocrine Disease.
    Pediatr Endocrinol Rev; 2004 Dec; 2 Suppl 2():276-8. PubMed ID: 16462708
    [Abstract] [Full Text] [Related]

  • 5. The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus.
    Chiasson JL, Gomis R, Hanefeld M, Josse RG, Karasik A, Laakso M.
    Diabetes Care; 1998 Oct; 21(10):1720-5. PubMed ID: 9773737
    [Abstract] [Full Text] [Related]

  • 6. Cardiovascular benefits of acarbose in impaired glucose tolerance and type 2 diabetes.
    Zeymer U.
    Int J Cardiol; 2006 Feb 08; 107(1):11-20. PubMed ID: 16337493
    [Abstract] [Full Text] [Related]

  • 7. Clinical experience with acarbose as first line therapy in NIDDM.
    Fölsch UR.
    Clin Invest Med; 1995 Aug 08; 18(4):312-7. PubMed ID: 8549018
    [Abstract] [Full Text] [Related]

  • 8. Long-term effect of alpha-glucosidase inhibitor on late dumping syndrome.
    Hasegawa T, Yoneda M, Nakamura K, Ohnishi K, Harada H, Kyouda T, Yoshida Y, Makino I.
    J Gastroenterol Hepatol; 1998 Dec 08; 13(12):1201-6. PubMed ID: 9918426
    [Abstract] [Full Text] [Related]

  • 9. Effect of lowering postprandial hyperglycemia on insulin secretion in older people with impaired glucose tolerance.
    Chang AM, Smith MJ, Bloem CJ, Galecki AT, Halter JB.
    Am J Physiol Endocrinol Metab; 2004 Nov 08; 287(5):E906-11. PubMed ID: 15213063
    [Abstract] [Full Text] [Related]

  • 10. Rosiglitazone improves insulin sensitivity in nonobese subjects with impaired glucose tolerance: the role of adiponectin and C-reactive protein.
    Hung YJ, Lin SH, Pei D, Kuo SW, Hsieh CH, He CT, Hsing Lee C, Fan SC, Sheu WH.
    Metabolism; 2006 Apr 08; 55(4):439-44. PubMed ID: 16546473
    [Abstract] [Full Text] [Related]

  • 11. Acarbose improves fibrinolytic activity in patients with impaired glucose tolerance.
    Shinoda Y, Inoue I, Nakano T, Seo M, Sassa M, Goto S, Awata T, Komoda T, Katayama S.
    Metabolism; 2006 Jul 08; 55(7):935-9. PubMed ID: 16784967
    [Abstract] [Full Text] [Related]

  • 12. A pilot study to examine the feasibility of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetes.
    Marbury TC, Schwartz S, Rosenberg MA, Jariwala N, Becker RH, Johnston PS.
    Exp Clin Endocrinol Diabetes; 2008 May 08; 116(5):282-8. PubMed ID: 18484560
    [Abstract] [Full Text] [Related]

  • 13. [Postprandial blood glucose as the driving force in pathogenesis of type 2 diabetes].
    Liebl A.
    Med Klin (Munich); 2003 Oct 15; 98 Suppl 1():7-11. PubMed ID: 14694835
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Clinical efficacy of acarbose in diabetes mellitus: a critical review of controlled trials.
    Scheen AJ.
    Diabetes Metab; 1998 Sep 15; 24(4):311-20. PubMed ID: 9805641
    [Abstract] [Full Text] [Related]

  • 17. [Clinical experience with an alpha glucosidase inhibitor (acarbose) in the treatment of non-insulin-dependent diabetes. Multicenter study].
    García de los Ríos M, Mujica V, Muñoz S, Durruty P, Larenas G, López MI, Kuzmanic A, Pérez J, Flaskamp R, Cumsille F.
    Rev Med Chil; 1997 Aug 15; 125(8):856-62. PubMed ID: 9580485
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.